{"url_path":"/sec/dcoy/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-286737-index.html","accession_number":"0001193125-26-286737","cik":"0001615219","ticker":"DCOY","issuer_name":"Decoy Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-286737-index.html","primary_entity_key":"0001615219","primary_entity_name":"Decoy Therapeutics Inc."},"word_count":173,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit Number\n\n \n\nExhibit Description\n\n4.1\n\n \n\n[Form of Pre-Funded Warrant](dcoy-ex4_1.htm)\n\n4.2\n\n \n\n[Form of Series A Common Warrant](dcoy-ex4_2.htm)\n\n4.3\n\n \n\n[Form of Series B Common Warrant](dcoy-ex4_3.htm)\n\n4.4\n\n \n\n[Form of Series C Common Warrant](dcoy-ex4_4.htm)\n\n4.5\n\n \n\n[Form of Placement Agent Warrant](dcoy-ex4_5.htm)\n\n10.1\n\n \n\n[Securities Purchase Agreement, dated June 26, 2026, by and between the Company and the Purchase](dcoy-ex10_1.htm)r\n\n10.2\n\n \n\n[Registration Rights Agreement, dated June 26, 2026, by and between the Company and the Purchase](dcoy-ex10_2.htm)r\n\n10.3\n\n \n\n[Form of Lock-Up Agreement](dcoy-ex10_3.htm)\n\n10.4\n\n \n\n[Placement Agency Agreement, dated June 26 2026, by and between the Company and Curvature Securities, LLC](dcoy-ex10_4.htm)\n\n99.1\n\n \n\n[Press Release, dated June 26, 2026](dcoy-ex99_1.htm)\n\n99.2\n\n \n\n[Investor Presentation](dcoy-ex99_2.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\nDecoy Therapeutics inc.\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: June 29, 2026\n\nBy:\n\n/s/ Mark J. Rosenblum\n\n \n\n \n\nMark J. Rosenblum\n\n \n\n \n\nExecutive Vice President and Chief Financial Officer"}